


CofC

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Alexander KOZAK, et al.

Serial No.: 09/856,009

Filed: May 16, 2001

Patent No.: 6,730,696 B1

Issued: May 4, 2004

For: **PHOSPHOLIPID DERIVATIVES OF NON-
STEROIDAL ANTI-INFLAMMATORY
DRUGS**

Examiner: Sonia Wright (Art Unit: 1626)

Certificate
JAN 04 2006
of CorrectionAttn: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 22, 2005

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322(a)

S I R:

In accordance with 37 C.F.R. §1.322(a)(1)(i), Applicants hereby request that the U.S. Patent and Trademark Office issue a Certificate of Correction for the above-identified U.S. patent correcting the claims as issued in this patent. Enclosed is Form PTO-1050 (four (4) sheets) showing the correction in this patent, namely, corrected claims 1, 2, 8, 9, 10 and 16. The error in not amending claims 1, 2, 8, 9, 10 and 16 prior to their issuance in this patent is an error that arose at the USPTO, as set forth below.


On October 7, 2003, the undersigned attorney for Applicants was contacted by the Examiner for this application, who indicated that she was prepared to allow the claims but with certain specified changes. On October 14, 2003, the undersigned attorney discussed this matter with the Examiner and reached an agreement with the Examiner as to the amendments of claims. On October 14, 2003, Applicants submitted an Amendment and Statement of Substance of Interview in order to implement the changes as discussed with the Examiner, wherein claims 1,

2, 10, 11, 12 and 20 of the application, which issued as claims 1, 2, 8, 9, 10 and 16 in the patent, were amended. On October 20, 2003, the USPTO Issued a Notice of Allowance for this application.

Attached hereto as Attachment A is a copy of the Amendment and Statement of Substance of Interview as transmitted to the USPTO by facsimile on October 14, 2003, along with copies of a Certificate of Transmission and the facsimile confirmation sheet showing that all pages were received by the USPTO. Attached hereto as Attachment B is a copy of a printout from the USPTO web site showing the transaction history for the prosecution of this patent application, which shows a Supplemental Response having been received by the USPTO on October 14, 2003. It is clear that the USPTO received a copy of the Amendment and Statement of Substance of Interview, wherein claims 1, 2, 8, 9, 10 and 16 of the patent were amended. However, the USPTO erroneously printed the patent without these amendments having been entered. Accordingly, a Certificate of Correction is now needed in order to ensure that claims 1, 2, 8, 9, 10 and 16 as amended are printed with this patent.

Because this error is the fault of the USPTO, no fee for issuance of a Certificate of Correction is due. If any fees are deemed to be due in connection with this Request, the Commissioner is authorized to charge payment to Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC


By: 
Morey B. Wildes
Reg. No. 36,968

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

CLIFFORD M. DAVIDSON
LESLYE B. DAVIDSON
CARY S. KAPPEL
WILLIAM C. GEHRIS
MOREY B. WILDES
ROBERT J. PARADISO
ERIK R. SWANSON***
THOMAS P. CANTY***

FELIX L. D'ARIENZO, JR.

DAVID G. KNASIAK
RICHARD V. ZANZALARI
BENJAMIN S. DIMARCO*
FRANKLIN S. ABRAMS
MICHELLE I. BLAT**
HEIDI M. STRUSE



NEW YORK
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 SEVENTH AVENUE, 14TH FLOOR
NEW YORK, NY 10018
T. 212-736-1940
F. 212-736-2427
DDK@DDKPATENT.COM

FRANKFURT
DAVIDSON, DAVIDSON & KAPPEL EUROPE, LLC
ARNDTSTRASSE 11
60325 FRANKFURT AM MAIN, GERMANY
T. +49 (69) 788 088-0
F. +49 (69) 788 088-29
FRANKFURT@DDKPATENT.COM

*ADMITTED IN NEW JERSEY ONLY
**ADMITTED IN CONNECTICUT ONLY
***DDK EUROPE

FACSIMILE TRANSMITTAL

FROM: Morey B. Wildes

DATE: October 14, 2003

OUR REF: 800.1012

NO. OF PAGES (including cover): 13

PLEASE DELIVER THE FOLLOWING TO:

Recipients(s):

Fax Number:

Examiner Sonya Wright
U.S. Patent and Trademark Office
Group 1626

(703) 746-3146

MESSAGE:

CONFIDENTIALITY NOTICE: The documents accompanying this facsimile transmission contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this facsimile information is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us.

**IF THERE ARE ANY PROBLEMS WITH RECEPTION OF THIS FAX,
PLEASE CALL OR FAX SENDER TO ADVISE. THANK YOU.**


**TRANSMITTAL
FORM***(to be used for all correspondence after initial filing)*

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/856,009	
	Filing Date	May 16, 2001	
	First Named Inventor	KOZAK, et al.	
	Group Art Unit	1626	
	Examiner Name	Sonya N. Wright	
Total Number of Pages in This Submission	12	Attorney Docket Number	800.1012

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>		
<table border="1"> <tr> <td>Remarks</td> <td></td> </tr> </table>			Remarks	
Remarks				

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name	Davidson, Davidson & Kappel, LLC				
Address	485 Seventh Avenue, 14 th Floor				
City	New York	State	NY	Zip Code	10018
Country	USA	Telephone	(212) 736-1940	Fax	(212) 736-2427
Individual name	Morey B. Wildes				
Signature					
Date	October 14, 2003				

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Typed or printed name	Morey B. Wildes		
Signature		Date	October 14, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Alexander KOZAK, et al.
Serial No.: 09/856,009
Filed: May 16, 2001
For: **PHOSPHOLIPID DERIVATIVES OF NON-
STEROIDAL ANTI-INFLAMMATORY DRUGS**
Examiner: Sonya N. Wright
Art Unit: 1626

MAIL STOP: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 14, 2003

**AMENDMENT AND
STATEMENT OF SUBSTANCE OF INTERVIEW**

S I R:

In response to recent communications from and an interview by an attorney for Applicants with Examiner Sonya N. Wright in the U.S. Patent and Trademark Office in connection with the above-identified application, Applicants hereby amend this application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 10 of this paper.


IN THE CLAIMS:

Please amend claims 1, 2, 10, 11, 12 and 20 as indicated below.

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X-, wherein Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino and thio groups.

2. (Currently Amended) The compound according to claim 1, wherein the conjugated residue of ~~the nonsteroidal ant-inflammatory drug~~ indomethacin is pharmacologically inactive.

3. (Original) The compound according to claim 1, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

4. (Original) The compound according to claim 3, wherein said lipase is a phospholipase.

5. (Original) The compound according to claim 4, wherein said phospholipase is phospholipase A₂ (PLA₂).

6. (Original) The compound according to claim 1, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

7. (Original) The compound according to claim 1, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

8-9. (Canceled)

10. (Currently Amended) The compound according to claim 1 selected from the group consisting of:

~~1-Stearoyl 2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{8-[2-(2,6-dichloroaniline)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{12-[2-(2,6-dichloroaniline)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and~~

~~1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{3-[α -methyl 4-(2-methylpropyl)benzeneacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{6-[α -methyl 4-(2-methylpropyl)benzeneacetamido]hexanoyl}-sn-glycero-3-phosphocholine,~~


~~1-Stearoyl 2-{3-[(S)-6-methoxy- α -methyl 2-naphtaleneacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{4-[(S)-6-methoxy- α -methyl 2-naphtaleneacetamido]butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{6-[(S)-6-methoxy- α -methyl 2-naphtaleneacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and~~

~~1-Stearoyl 2-{4-[2-(6-methoxynaphtyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine.~~

11. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, $-\text{C}(\text{O})-\text{Z}-\text{X}-$, wherein Z is a saturated hydrocarbon chain having from 3 to 15 carbon atoms, and X is selected from amino and thio groups.

12. (Previously Amended) The pharmaceutical composition according to claim 11, wherein $-\text{C}(\text{O})-\text{Z}-\text{X}-\text{D}$ is an inactive derivative of indomethacin.

13. (Original) The pharmaceutical composition according to claim 11, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

14. (Original) The pharmaceutical composition according to claim 13, wherein said lipase is a phospholipase.

15. (Original) The pharmaceutical composition according to claim 14, wherein said phospholipase is phospholipase A₂ (PLA₂).

16. (Original) The pharmaceutical composition according to claim 11, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

17. (Original) The pharmaceutical composition according to claim 11, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

18-19. (Canceled)

20. (Currently Amended) The pharmaceutical composition according to claim 11, wherein said compound of the general formula I is selected from the group consisting of:

~~1-Stearoyl 2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl 2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,~~

1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine;

~~1-Stearoyl-2-{3-[α -methyl-4-(2-methylpropyl)benzeneacetamido]propanoyl}-sn-glycero-3-phosphocholine;~~

~~1-Stearoyl-2-{6-[α -methyl-4-(2-methylpropyl)benzeneacetamido]hexanoyl}-sn-glycero-3-phosphocholine;~~

~~1-Stearoyl-2-{3-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido]propanoyl}-sn-glycero-3-phosphocholine;~~

~~1-Stearoyl-2-{4-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido]butanoyl}-sn-glycero-3-phosphocholine;~~

~~1-Stearoyl-2-{6-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido]hexanoyl}-sn-glycero-3-phosphocholine; and~~

~~1-Stearoyl-2-{4-[2-(6-methoxynaphtyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine.~~

21. (Previously Amended) The pharmaceutical composition according to claim 11, in the form of solutions, suspensions, capsules, tablets, aerosols, gels, ointments or suppositories.

22. (Previously Amended) The pharmaceutical composition according to claim 11 for oral, ocular, nasal, parenteral, topical or rectal administration.

23. (Original) The pharmaceutical composition according to claim 22 for oral administration.

24. (Original) The pharmaceutical composition according to claim 22 for nasal administration.

25. (Previously Amended) The pharmaceutical composition according to claim 11 for the treatment of a ~~disease or disorder related to an~~ inflammatory ^{or} condition.

26. (Original) The pharmaceutical composition according to claim ~~25~~¹¹, wherein said

disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

27. (Canceled)

28. (Previously Amended) *inflammatory* A method for treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 11.

29. (Original) *inflammatory* The method according to claim 28, wherein said disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

30. (Previously Amended) A process for the synthesis of compounds of the general formula I as defined in claim 1, comprising:

- (i) providing a molecule $y-X-Z-COOH$, wherein y is selected from H and OH, Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino, and thio groups;
- (ii) replacing y with an appropriate blocking group, B , selected from the group consisting of benzyl chloromate, benzyloxycarbonate, diphenylcarbinol and trimethylacetamidocarbinol;
- (iii) preparing an anhydride of the molecule $B-X-Z-COOH$ by employing a reagent to remove one molecule of water from two protected bridging groups;

- (iv) acylating a lyso-lecithin by the anhydride of step (iii) to yield 1-acyl-2-acyl(X-B)-sn-glycero-3 phospholipid by dissolving said anhydride and said lyso-lecithin in an organic solvent in the presence of a catalyst;
- (v) removing the blocking group B from the functional group X; and
- (vi) coupling a nonsteroidal anti-inflammatory drug D comprising indomethacin to the functional group X in an organic solvent in the presence of reagents that enable a condensation reaction wherein water molecules are removed, thus, generating a molecule of the general Formula I.

31. (Original) The process according to claim 30 wherein the protected functional group X is -NH.

32. (Original) The process according to claim 30 wherein the phospholipid of step (iv) is phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine.

33. (Canceled)

REMARKS

Claims 1-7, 10-17, 20-26 and 28-32 are in this application, as previously amended by the Applicant in a Preliminary Amendment filed May 16, 2001, in a Supplemental Preliminary Amendment dated February 26, 2003 and in a Response to Office Action dated July 15, 2003.

On October 7, 2003, the undersigned attorney was contacted by the Examiner, who indicated that she was prepared to allow the claims but with certain changes. According to the Examiner, (1) claims 2 and 12 should be canceled, because the amendment of the definition of D in claims 1 and 11 have made these claims extraneous, and (2) the first six and last six compounds listed in claims 10 and 20 should be deleted, leaving only those middle five compounds with an indolyl group, because claims 1 and 11 have been limited to indomethacin.

On October 14, 2003, the undersigned attorney contacted the Examiner in reply and advised her that (1) claims 2 and 12 need not be canceled, because they are of different scope than their parent claims 1 and 11, although they are being amended to specifically recite indomethacin, as in the parent claims, and that (2) the first six and last six compounds listed in claims 10 and 20 may be deleted, leaving only those middle five compounds with an indolyl group. The undersigned attorney also advised the Examiner during this interview that the words "residue of" in the definition of D in claims 1 and 11 had inadvertently been deleted in the July 15, 2003 amendment.

The Examiner agreed with not canceling claims 2 and 12.

This amendment is being submitted in order to implement these enumerated changes, as discussed with the Examiner.

Conclusion


Reconsideration of the present application, as amended, is requested. It is respectfully submitted that claims 1-7, 10-17, 20-26 and 28-32 remaining in this application are patentable.

If, upon review, the Examiner is unable to issue an immediate Notice of Allowance, the Examiner is respectfully requested to telephone Applicant's undersigned attorney in order to resolve any outstanding issues and advance the prosecution of the case.

An early and favorable action on the merits is earnestly solicited.

Respectfully Submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: _____



Morey B. Wildes
Reg. No. 36,968

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

* * * COMMUNICATION RESULT REPORT (OCT. 14. 2003 3:53PM) * * *

TTI DDK

TRANSMITTED/STORED OCT. 14. 2003 3:49PM

FILE MODE	OPTION	ADDRESS	RESULT	PAGE
8490 MEMORY TX		917037463146	OK	13/13

REASON FOR ERROR
 E-1) HANG UP OR LINE FAIL
 E-3) NO ANSWER

E-2) BUSY
 E-4) NO FACSIMILE CONNECTION

CLIFFORD M. DAVIDSON
 LESLYE B. DAVIDSON
 CARY S. KAPPEL
 WILLIAM C. GEHRIS
 MOREY B. WILDES
 ROBERT J. PARADISO
 ERIK R. SWANSON***
 THOMAS P. CANTY**

FELIX L. D'ARIENZO, JR.

DAVID G. KNASIAK
 RICHARD V. ZANZALARI
 BENJAMIN S. DIMARCO*
 FRANKLIN S. ABRAMS
 MICHELLE I. BLAT**
 HEIDI M. STRLISE



NEW YORK
 DAVIDSON, DAVIDSON & KAPPEL, LLC
 485 SEVENTH AVENUE, 14TH FLOOR
 NEW YORK, NY 10018
 T. 212-736-1940
 F. 212-736-2427
 DDK@DDKPATENT.COM

FRANKFURT
 DAVIDSON, DAVIDSON & KAPPEL EUROPE, LLC
 ARNDTSTRASSE 11
 60325 FRANKFURT AM MAIN, GERMANY
 T. +49 (69) 788 088-0
 F. +49 (69) 788 088-29
 FRANKFURT@DDKPATENT.COM

*ADMITTED IN NEW JERSEY ONLY
 **ADMITTED IN CONNECTICUT ONLY
 ***DDK EUROPE

FACSIMILE TRANSMITTAL

FROM: Morey B. Wildes

DATE: October 14, 2003

OUR REF: 800.1012

NO. OF PAGES (including cover): 13

PLEASE DELIVER THE FOLLOWING TO:

Recipients(s):

Examiner Sonya Wright
 U.S. Patent and Trademark Office
 Group 1626

Fax Number:

(703) 746-3146

MESSAGE:

CONFIDENTIALITY NOTICE: The documents accompanying this facsimile transmission contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this facsimile information is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us.

IF THERE ARE ANY PROBLEMS WITH RECEPTION OF THIS FAX,
 PLEASE CALL OR FAX SENDER TO ADVISE. THANK YOU.

Printer Friendly

09/856,009

PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Transaction History

Date	Contents Description
05-04-2004	Recordation of Patent Grant Mailed
04-15-2004	Issue Notification Mailed
05-04-2004	Patent Issue Date Used in PTA Calculation
03-16-2004	Receipt into Pubs
03-11-2004	Application Is Considered Ready for Issue
01-08-2004	Issue Fee Payment Verified
05-16-2001	Workflow - Drawings Finished
03-02-2004	Receipt into Pubs
01-08-2004	Issue Fee Payment Received
12-12-2003	Workflow - File Sent to Contractor
10-20-2003	Mail Notice of Allowance
10-20-2003	Mail Examiner's Amendment
10-17-2003	Notice of Allowance Data Verification Completed
10-17-2003	Case Docketed to Examiner in GAU
10-17-2003	Examiner's Amendment Communication
10-17-2003	Date Forwarded to Examiner
10-14-2003	Supplemental Response
08-12-2003	Date Forwarded to Examiner
08-04-2003	Supplemental Response
08-01-2003	Date Forwarded to Examiner
07-17-2003	Response after Non-Final Action
04-15-2003	Mail Non-Final Rejection
04-07-2003	Non-Final Rejection
03-04-2003	Preliminary Amendment
02-26-2003	Date Forwarded to Examiner
02-11-2003	Response to Election / Restriction Filed
01-06-2003	Mail Restriction Requirement
01-06-2003	Requirement for Restriction / Election
11-21-2002	Case Docketed to Examiner in GAU
09-04-2001	Information Disclosure Statement (IDS) Filed
07-21-2001	Case Docketed to Examiner in GAU
05-16-2001	Preliminary Amendment
05-16-2001	Request for Foreign Priority (Priority Papers May Be Included)
07-10-2001	Application Dispatched from OIPE
07-06-2001	IFW Scan & PACR Auto Security Review
06-28-2001	Correspondence Address Change
06-25-2001	Released to OIPE
06-26-2001	Notice of DO/EO Acceptance Mailed
06-13-2001	371 Application Preexamination Docketing
06-13-2001	371 Application Preexamination Docketing
06-08-2001	371 Application Preexamination Docketing
05-16-2001	Receipt of 371 Request
06-08-2001	Correspondence Address Change
05-16-2001	Initial Exam Team nn

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696

Page 1 of 4

APPLICATION NO.: 09/856,009


ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In the claims, claims 1, 2, 8, 9, 10 and 16 should be replaced with the following amended claims 1, 2, 8, 9, 10 and 16:

1. A compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R₁ is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;

R₂ is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X-, wherein Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino and thio groups.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696

Page 2 of 4

APPLICATION NO.: 09/856,009

ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

(Continued)

2. The compound according to claim 1, wherein the conjugated residue of indomethacin is pharmacologically inactive.
8. The compound according to claim 1 selected from the group consisting of:
- 1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl} sn-glycero-3-phosphocholine,
 - 1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl} sn-glycero-3-phosphocholine,
 - 1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl} sn-glycero-3-phosphocholine,
 - 1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl} sn-glycero-3-phosphocholine, and
 - 1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl} sn-glycero-3-phosphocholine.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696

Page 3 of 4

APPLICATION NO.: 09/856,009


ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

(Continued)

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X-, wherein Z is a saturated hydrocarbon chain having from 3 to 15 carbon atoms, and X is selected from amino and thio groups.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696

Page 4 of 4

APPLICATION NO.: 09/856,009

ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

(Continued)

10. The pharmaceutical composition according to claim 9, wherein C(O)-Z-X-D is an inactive derivative of indomethacin.

16. The pharmaceutical composition according to claim 9, wherein said compound of the general formula I is selected from the group consisting of:

1-Stearoyl-2-[3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido] propanoyl]-sn-glycero-3-phosphocholine,

1-Stearoyl-2-[4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl]-sn-glycero-3-phosphocholine,

1-Stearoyl-2-[5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl]-sn-glycero-3-phosphocholine,

1-Stearoyl-2-[6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl]-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-[8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl]-sn-glycero-3-phosphocholine.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.